Mead Johnson Lawsuit Over Enfamil NEC Risks Results in Defense Verdict

A federal jury in Chicago issued a defense verdict on behalf of Mead Johnson, manufacturer of Enfamil infant formula, in the first scheduled bellwether trial in federal Enfamil NEC litigation. The jury determined that Mead Johnson was not liable for the death of a preterm newborn who had been fed the company's specialized formula product.

Mead Johnson and Abbott Laboratories (maker of Similac) together face nearly 850 necrotizing enterocolitis lawsuits filed in federal courts nationwide. Plaintiffs—typically parents of preterm infants—allege that manufacturers failed to warn about the potential increased risk of NEC associated with cow's milk-based formula products designed for preterm nutrition.

Necrotizing enterocolitis is a serious condition in which harmful bacteria infiltrate and damage the infant's intestinal walls, causing tissue death, severe complications, and potentially death. Preterm newborns face elevated susceptibility due to their underdeveloped gastrointestinal systems. Treatment typically involves aggressive antibiotics and sometimes surgical removal of portions of the gastrointestinal tract, potentially resulting in lifelong health complications and ongoing medical care needs.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.